Maravai LifeSciences (MRVI) Competitors $3.33 +0.02 (+0.60%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$3.36 +0.03 (+0.78%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRVI vs. VKTX, CGON, MOR, GMTX, IMVT, APLS, RARE, HCM, KNSA, and OGNShould you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Viking Therapeutics (VKTX), CG Oncology (CGON), MorphoSys (MOR), Gemini Therapeutics (GMTX), Immunovant (IMVT), Apellis Pharmaceuticals (APLS), Ultragenyx Pharmaceutical (RARE), HUTCHMED (HCM), Kiniksa Pharmaceuticals International (KNSA), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Maravai LifeSciences vs. Its Competitors Viking Therapeutics CG Oncology MorphoSys Gemini Therapeutics Immunovant Apellis Pharmaceuticals Ultragenyx Pharmaceutical HUTCHMED Kiniksa Pharmaceuticals International Organon & Co. Maravai LifeSciences (NASDAQ:MRVI) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, profitability, risk, earnings, dividends and valuation. Is MRVI or VKTX more profitable? Viking Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -90.03%. Maravai LifeSciences' return on equity of -17.60% beat Viking Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Maravai LifeSciences-90.03% -17.60% -9.30% Viking Therapeutics N/A -19.98%-19.38% Do analysts prefer MRVI or VKTX? Maravai LifeSciences presently has a consensus price target of $5.22, indicating a potential upside of 56.72%. Viking Therapeutics has a consensus price target of $86.42, indicating a potential upside of 166.97%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Viking Therapeutics is more favorable than Maravai LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maravai LifeSciences 2 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.08Viking Therapeutics 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.86 Does the media prefer MRVI or VKTX? In the previous week, Viking Therapeutics had 8 more articles in the media than Maravai LifeSciences. MarketBeat recorded 11 mentions for Viking Therapeutics and 3 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.63 beat Viking Therapeutics' score of 0.53 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MRVI or VKTX? Maravai LifeSciences has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Do insiders and institutionals believe in MRVI or VKTX? 50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 2.1% of Maravai LifeSciences shares are owned by company insiders. Comparatively, 4.1% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has better valuation & earnings, MRVI or VKTX? Viking Therapeutics has lower revenue, but higher earnings than Maravai LifeSciences. Viking Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMaravai LifeSciences$259.18M3.28-$144.85M-$1.36-2.45Viking TherapeuticsN/AN/A-$109.96M-$1.53-21.16 SummaryViking Therapeutics beats Maravai LifeSciences on 10 of the 16 factors compared between the two stocks. Get Maravai LifeSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRVI vs. The Competition Export to ExcelMetricMaravai LifeSciencesMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$845.25M$10.57B$6.09B$10.54BDividend YieldN/A1.87%5.69%4.71%P/E Ratio-2.4521.8785.3527.60Price / Sales3.2832.49539.78202.41Price / Cash5.3625.4637.9261.55Price / Book1.463.4513.016.76Net Income-$144.85M$208.83M$3.30B$275.88M7 Day Performance12.12%1.63%4.34%2.81%1 Month Performance25.19%2.06%9.49%9.24%1 Year Performance-56.70%-5.12%84.83%35.42% Maravai LifeSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRVIMaravai LifeSciences3.3685 of 5 stars$3.33+0.6%$5.22+56.7%-56.6%$845.25M$259.18M-2.45610VKTXViking Therapeutics4.0124 of 5 stars$25.81+0.9%$86.42+234.8%-51.5%$2.88BN/A-16.8720Analyst ForecastGap UpCGONCG Oncology2.3155 of 5 stars$39.08+4.1%$56.55+44.7%+16.9%$2.86B$1.14M-22.0861Analyst ForecastGap UpMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730GMTXGemini TherapeuticsN/A$65.55+4.9%N/A+43.4%$2.84BN/A-65.5530IMVTImmunovant1.8768 of 5 stars$16.06-1.0%$33.60+109.2%-45.7%$2.83BN/A-5.64120APLSApellis Pharmaceuticals4.0659 of 5 stars$22.65+1.3%$33.29+47.0%-9.1%$2.83B$781.37M-12.44770Analyst ForecastRAREUltragenyx Pharmaceutical4.387 of 5 stars$30.36+4.4%$81.50+168.4%-42.1%$2.80B$560.23M-5.491,294Analyst ForecastHCMHUTCHMED2.4168 of 5 stars$15.66+0.1%$20.88+33.3%-20.5%$2.73B$630.20M0.001,811Analyst ForecastKNSAKiniksa Pharmaceuticals International3.649 of 5 stars$38.77+6.2%$44.29+14.2%+56.6%$2.70B$423.24M969.49220Analyst DowngradeHigh Trading VolumeOGNOrganon & Co.4.7515 of 5 stars$10.35+1.3%$17.33+67.6%-43.4%$2.65B$6.40B3.854,000Analyst Forecast Related Companies and Tools Related Companies VKTX Alternatives CGON Alternatives MOR Alternatives GMTX Alternatives IMVT Alternatives APLS Alternatives RARE Alternatives HCM Alternatives KNSA Alternatives OGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRVI) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
